Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
| ▸ | MC3R | P41968 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17035691 | 0.79 | ERN1 (0.35) | ERN1ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL16882893 | 0.74 | HDAC3 (0.35) | ERN1ALDH1A1LMNATSHRHTT | |
| SCHEMBL566202 | 0.73 | GAA (0.43) | ALDH1A1KDM4ELMNATSHRHTT | |
| SCHEMBL9602125 | 0.72 | MAOB (0.49) | ALDH1A1KDM4ELMNASMN1; SMN2HSD17B10 | |
| SCHEMBL9602133 | 0.72 | MAOB (0.49) | ALDH1A1KDM4ELMNASMN1; SMN2HSD17B10 | |
| SCHEMBL17254245 | 0.70 | ERN1 (0.37) | ERN1ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL3189250 | 0.68 | TSHR (0.44) | ALDH1A1KDM4ELMNATSHRHTT | |
| SCHEMBL1527119 | 0.68 | TSHR (0.39) | ALDH1A1KDM4ELMNATSHRHTT | |
| SCHEMBL480683 | 0.68 | LMNA (0.39) | ALDH1A1KDM4ELMNATSHRHTT | |
| SCHEMBL3806350 | 0.68 | ERN1 (0.42) | ERN1ALDH1A1KDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | GILLESPIE PAUL | 2009-01-22 | — | — | US | disclosed |
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | GILLESPIE PAUL | 2009-01-22 | — | — | US | disclosed |
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | GILLESPIE PAUL | 2009-01-22 | — | — | US | disclosed |
| WO-2007070393-A2 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1758895-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009734-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | ERN1 3348/4885ALDH1A1 2424/4885IMPDH2 2894/4885 |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | ERN1 1873/4885ALDH1A1 3889/4885IMPDH2 3871/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | ERN1 1853/4885ALDH1A1 3670/4885IMPDH2 4196/4885 |
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | GNRHR, GHRHR, LHCGR | ERN1 3424/4885ALDH1A1 4733/4885IMPDH2 3983/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | ERN1 3841/4885ALDH1A1 1723/4885IMPDH2 1468/4885 |
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | HSD17B1, HSD17B2, HSD11B1 | ERN1 2332/4885ALDH1A1 64/4885IMPDH2 156/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | ERN1 3969/4885ALDH1A1 1026/4885IMPDH2 4140/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | ERN1 1853/4885ALDH1A1 3670/4885IMPDH2 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.